RELIVE Investigators

Independent

SCHOLARLY PAPERS

1

DOWNLOADS

36

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Doxorubicin-Loaded Nanoparticles for Patients with Advanced Hepatocellular Carcinoma after Failure of Sorafenib: RELIVE, a Phase-3 Trial

Number of pages: 162 Posted: 13 Mar 2019
Croix Rousse Hospital - Hepatology Unit, Hôpital Haut Lévèque, University of Saint Etienne - Centre Hospitalier Universitaire de Saint-Étienne, Université Paris Sud - Hôpital Paul Brousse, University Hospital, Nancy, CHU de Nantes, Hôpital Saint-Eloi, Hôpital de la Conception, Hôpital Civil, Hôpital Nord, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), UCL Saint-Luc, Université Cote d'Azur - Centre Hospitalier Universitaire de Nice, Hôpital Archet, University of Hamburg - University Medical Center Hamburg-Eppendorf, Ain Shams University, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Besançon - University Hospital Besançon, Menoufia University - Department of Hepatology and Gastroenterology, Pennsylvania State University - Milton S. Hershey Medical Center, Onxeo, Onxeo, eXYSTAT, Onxeo and Independent
Downloads 36 (801,551)

Abstract:

Loading...

Doxorubicin HCC RELIVE randomization